A clinical update in polycythemia vera and essential thrombocythemia

Ayalew Tefferi, Lawrence A. Solberg, Murray N. Silverstein

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Polycythemia vera and essential thrombocythemia pose specific management issues that distinguish them from other chronic myeloproliferative disorders. They are associated with a better prognosis, as well as a variable risk of thrombohemorrhagic complications. In addition, essential thrombocythemia occurs comparatively more often in young people and women. Treatment strategies for patients with polycythemia vera and essential thrombocythemia must consider the possibility of long-term survival, morbidity from thrombotic complications, transformation into myelofibrosis with myeloid metaplasia or acute myeloid leukemia, and the effect of specific therapies on the incidence of leukemic transformation and on pregnancy. There is increasing concern about the possible leukemogenic effect of hydroxyurea. Newer therapeutic agents, including interferon alpha and anagrelide, are being used more often. Ongoing studies are reexamining the effects of low- dose aspirin in preventing thrombotic complications. (C) 2000 by Excerpta Medica, Inc.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalAmerican Journal of Medicine
Volume109
Issue number2
DOIs
StatePublished - Aug 1 2000

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Myeloproliferative Disorders
Primary Myelofibrosis
Hydroxyurea
Interferon-alpha
Acute Myeloid Leukemia
Aspirin
Therapeutics
Morbidity
Pregnancy
Survival
Incidence

ASJC Scopus subject areas

  • Nursing(all)

Cite this

A clinical update in polycythemia vera and essential thrombocythemia. / Tefferi, Ayalew; Solberg, Lawrence A.; Silverstein, Murray N.

In: American Journal of Medicine, Vol. 109, No. 2, 01.08.2000, p. 141-149.

Research output: Contribution to journalArticle

Tefferi, Ayalew ; Solberg, Lawrence A. ; Silverstein, Murray N. / A clinical update in polycythemia vera and essential thrombocythemia. In: American Journal of Medicine. 2000 ; Vol. 109, No. 2. pp. 141-149.
@article{668c12076fbb4983bd7585439291770c,
title = "A clinical update in polycythemia vera and essential thrombocythemia",
abstract = "Polycythemia vera and essential thrombocythemia pose specific management issues that distinguish them from other chronic myeloproliferative disorders. They are associated with a better prognosis, as well as a variable risk of thrombohemorrhagic complications. In addition, essential thrombocythemia occurs comparatively more often in young people and women. Treatment strategies for patients with polycythemia vera and essential thrombocythemia must consider the possibility of long-term survival, morbidity from thrombotic complications, transformation into myelofibrosis with myeloid metaplasia or acute myeloid leukemia, and the effect of specific therapies on the incidence of leukemic transformation and on pregnancy. There is increasing concern about the possible leukemogenic effect of hydroxyurea. Newer therapeutic agents, including interferon alpha and anagrelide, are being used more often. Ongoing studies are reexamining the effects of low- dose aspirin in preventing thrombotic complications. (C) 2000 by Excerpta Medica, Inc.",
author = "Ayalew Tefferi and Solberg, {Lawrence A.} and Silverstein, {Murray N.}",
year = "2000",
month = "8",
day = "1",
doi = "10.1016/S0002-9343(00)00449-6",
language = "English (US)",
volume = "109",
pages = "141--149",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A clinical update in polycythemia vera and essential thrombocythemia

AU - Tefferi, Ayalew

AU - Solberg, Lawrence A.

AU - Silverstein, Murray N.

PY - 2000/8/1

Y1 - 2000/8/1

N2 - Polycythemia vera and essential thrombocythemia pose specific management issues that distinguish them from other chronic myeloproliferative disorders. They are associated with a better prognosis, as well as a variable risk of thrombohemorrhagic complications. In addition, essential thrombocythemia occurs comparatively more often in young people and women. Treatment strategies for patients with polycythemia vera and essential thrombocythemia must consider the possibility of long-term survival, morbidity from thrombotic complications, transformation into myelofibrosis with myeloid metaplasia or acute myeloid leukemia, and the effect of specific therapies on the incidence of leukemic transformation and on pregnancy. There is increasing concern about the possible leukemogenic effect of hydroxyurea. Newer therapeutic agents, including interferon alpha and anagrelide, are being used more often. Ongoing studies are reexamining the effects of low- dose aspirin in preventing thrombotic complications. (C) 2000 by Excerpta Medica, Inc.

AB - Polycythemia vera and essential thrombocythemia pose specific management issues that distinguish them from other chronic myeloproliferative disorders. They are associated with a better prognosis, as well as a variable risk of thrombohemorrhagic complications. In addition, essential thrombocythemia occurs comparatively more often in young people and women. Treatment strategies for patients with polycythemia vera and essential thrombocythemia must consider the possibility of long-term survival, morbidity from thrombotic complications, transformation into myelofibrosis with myeloid metaplasia or acute myeloid leukemia, and the effect of specific therapies on the incidence of leukemic transformation and on pregnancy. There is increasing concern about the possible leukemogenic effect of hydroxyurea. Newer therapeutic agents, including interferon alpha and anagrelide, are being used more often. Ongoing studies are reexamining the effects of low- dose aspirin in preventing thrombotic complications. (C) 2000 by Excerpta Medica, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034254087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034254087&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(00)00449-6

DO - 10.1016/S0002-9343(00)00449-6

M3 - Article

C2 - 10967156

AN - SCOPUS:0034254087

VL - 109

SP - 141

EP - 149

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -